In addition to its antiangiogenic effect, the antitumour effect of lenvatinib was observed to partially depend on the existence of CD8+ T cells, TAM modulation, a reduced Treg proportion, and increased IFN-γ secretion by cytotoxic T cells in murine HCC models [108, 109]. The gene discussed is IFNG; the disease is hepatocellular carcinoma.